Rejuvenate Biomed Completes Last Patient Visit in Phase 2 Trial of RJx-01 in COPD-Related Muscle Weakness and Advances Regulatory Discussions for Sarcopenia
DIEPENBEEK, Belgium, Nov. 16, 2026 (GLOBE NEWSWIRE) -- Rejuvenate Biomed, a clinical-stage biopharmaceutical company developing combination therapeutics for age-related diseases, today announced that the last patient has completed the final study visit in its randomized, double-blind, placebo-controlled MINT-COPD Phase 2 trial. The trial assesses RJx-01, Rejuvenate Biomed’s lead investigational therapy, in older patients with chronic…
DIEPENBEEK, Belgium, Nov. 16, 2026 (GLOBE NEWSWIRE) -- Rejuvenate Biomed, a clinical-stage biopharmaceutical company developing combination therapeutics for age-related diseases, today announced that the last patient has completed the final study visit in its randomized, double-blind, placebo-controlled MINT-COPD Phase 2 trial. The trial assesses RJx-01, Rejuvenate Biomed’s lead investigational therapy, in older patients with chronic obstructive pulmonary disease (COPD) after hospitalization for a severe acute exacerbation that causes muscle weakness.
NEW YORK, Nov. 16, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of The Ensign Group, Inc. (NASDAQ: ENSG) between February 10, 2022 and June 18, 2026, both dates inclusive (the “Class Period”), of the important December 7, 2026 lead plaintiff deadline in the securities… ...
POCASSET, Mass., Nov. 16, 2026 (GLOBE NEWSWIRE) -- HII (NYSE: HII), a global leader in autonomous unmanned maritime systems, has received an updated U.S. Navy contract to build an additional 82 Lionfish small unmanned undersea vehicles (SUUVs), advancing production under a five-year program. ...
New class action for D-Wave (QBTS) urges investors to seek recovery for alleged securities fraud violations – lead plaintiff deadline of 12/15/2026 ...